Furthermore, CXCL1, “a CXCR2 ligand,” was found to be overexpressed in doxorubicin-treated mammary tumor cells, which was inhibited following CXCR2 knockdown (Sharma et al., 2013a). Here, CXCR2 is linked to breast cancer.